Enlivex Ltd. (ENLV): Total Liabilities
$392.05M
As of 2025-12-31
+231.1%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $392.05M | n/m | 2026-03-25, Balance as of period end |
| 2024-12-31 | $4.10M | -39.3% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $6.75M | -37.5% | 2025-04-30, Balance as of period end |
| 2022-12-31 | $10.80M | +6.9% | 2024-04-30, Balance as of period end |
| 2021-12-31 | $10.11M | +107.5% | 2023-04-10, Balance as of period end |
| 2020-12-31 | $4.87M | -22.4% | 2022-04-29, Balance as of period end |
| 2019-12-31 | $6.28M | +372.7% | 2021-04-30, Balance as of period end |
| 2018-12-31 | $1.33M | +26.8% | 2020-04-30, Balance as of period end |
| 2017-12-31 | $1.05M | n/a | 2019-04-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Enlivex Ltd. (ENLV) | 2025-12-31 | $392.05M | n/m |
| Insmed Inc (INSM) | 2025-12-31 | $1.53B | -12.3% |
| Alkermes plc. (ALKS) | 2025-12-31 | $667.70M | +13.1% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $663.99M | -20.5% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $3.10B | +10.7% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $501.83M | -0.1% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $1.36B | -5.5% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $840.49M | -0.6% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $2.21B | -9.3% |
Compare ENLV, INSM, ALKS, OPK side by side · Screen every company in Pharmaceutical Preparations ↗